Embracing the complexity of comorbidity

Journal of Clinical Oncology

Volumn 29, Issue 32, 2011, Pages 4217-4218

  Hurria, Arti ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; INSULIN; METFORMIN; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADULT COMORBIDITY EVALUATION 27 SCALE; AGING; BONE DESTRUCTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CHARLSON COMORBIDITY SCALE; CLINICAL DECISION MAKING; COMORBIDITY; CUMULATIVE ILLNESS RATING SCALE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED PRACTICE; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; NEUROPATHY; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NITRILES; TAMOXIFEN; TRIAZOLES;

EID: 81155133298     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5717     Document Type: Editorial

References (24)

1. Lee L, Cheung WY, Atkinson E, et al.: Impact of comorbidity on chemotherapy use and outcomes in solid tumors: A systematic review. J Clin Oncol 29:106-117, 2011
2. Ring A, Sestak I, Baum M, et al.: Influence of comorbidities and age on risk of death without recurrence: A retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. J Clin Oncol 29:4266-4272, 2011
3. Baum M, Budzar AU, Cuzick J, et al.: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
4. Yancik R: Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 80:1273-1283, 1997
5. Yancik R, Ries LG, Yates JW: Breast cancer in aging women: A populationbased study of contrasts in stage, surgery, and survival. Cancer 63:976-981, 1989 (Pubitemid 19063212)
6. Armstrong K, Eisen A, Weber B: Assessing the risk of breast cancer. New Engl J Med 342:564-571, 2000 (Pubitemid 30117898)
7. Smith BD, Smith GL, Hurria A, et al.: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27:2758-2765, 2009
8. Ries L, Eisner M, Kosary C, et al: SEER Cancer Statistics Review, 1975-2000. Bethesda, MD, National Cancer Institute, 2003. http://seer.cancer. gov/csr/1975-2000/
9. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994 (Pubitemid 24027550)
10. Eastell R, Adams JE, Coleman RE, et al.: Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230. J Clin Oncol 26:1051-1057, 2008
11. Lee JJ, Swain SM: Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 24:1633-1642, 2006 (Pubitemid 46638788)
12. Tan-Chiu E, Yothers G, Romond E, et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005 (Pubitemid 46657378)
13. Perez EA, Suman VJ, Davidson NE, et al.: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
14. Goodwin PJ, Ennis M, Pritchard KI, et al.: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
15. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009
16. Jiralerspong S, Palla SL, Giordano SH, et al.: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
17. Charlson M, Szatrowski TP, Peterson J, et al.: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994 (Pubitemid 24361532)
18. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
19. Fillenbaum GG, Smyer MA: The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol 36:428-434, 1981 (Pubitemid 11070078)
20. Hurria A, Cirrincione CT, Muss HB, et al.: Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 29:1290-1296, 2011
21. Piccirillo JF, Tierney RM, Costas I, et al.: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004 (Pubitemid 38669187)
22. Linn BS, Linn MW, Gurel L: Cumulative illness rating scale. J Am Geriatr Soc 16:622-626, 1968
23. Extermann M: Measuring comorbidity in older cancer patients. Eur J Cancer 36:453-471, 2000
24. Greenfield S, Apolone G, McNeil BJ, et al.: The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 31:141-154, 1993